Rogne Bioscience Inc.
Testing an anti-inflammatory human peptide for topical use against psoriasis
This article was originally published in Start Up
Executive Summary
The cost/efficacy argument over high-priced biological treatments for psoriasis has created a market opportunity that Rogne Bioscience Inc. intends to exploit. Instead of developing another injectable protein like so many others, the start-up is developing a topical formulation of a human peptide that it describes as “the off-switch for inflammation.”
You may also be interested in...
Skin Is In With Biomedical Investors
Unique market dynamics and plenty of exit options are attracting investors to dermatology. Profiles of Aclaris Therapeutics, Alexar Therapeutics, Rogne Bioscience, and Scioderm.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.